Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer
Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic CancerПодробнее
POLO Trial in Pancreatic CancerПодробнее
Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic CancerПодробнее
[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutationsПодробнее
![[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutations](https://img.youtube.com/vi/NeQlRaN3i1o/0.jpg)
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients wi...Подробнее
Olaparib in metastatic pancreatic cancer, the POLO trialПодробнее
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsПодробнее
Dr. Richards on Using PARP Inhibitors in Mutated Metastatic Pancreatic CancerПодробнее
POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancerПодробнее
Comment: POLO III trial for metastatic pancreatic cancerПодробнее
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-relate...Подробнее
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer ManagementПодробнее
Vincent Chung, MD, elaborates on BRCA mutations and pancreatic cancerПодробнее
Dr. Richards on PARP Inhibition in Pancreatic CancerПодробнее
Vincent Chung, MD, shares outcomes from the POLO trial metastatic pancreatic cancerПодробнее
Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic CancerПодробнее
Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them t...Подробнее
Dr. Richards on Genetic Testing in Metastatic Pancreatic CancerПодробнее
Dr. Macarulla Discusses Rapid Progressors in the POLO Trial in Pancreatic CancerПодробнее
